Recent News

• 03.30.2026 - Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
• 03.19.2026 - Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
• 03.19.2026 - Teva Releases Q1 2026 Aide Memoire

Recent Filings

• 03.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2026 - 144 Report of proposed sale of securities
• 03.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.09.2026 - 4 Statement of changes in beneficial ownership of securities